

DOUGLAS T. JONES

BIOTECHNOLOGY EXECUTIVE

Director of Medical Research/ Chief Operations Officer/ Program Manager

Dynamic Executive and medical doctor with a background in infectious diseases. Built a top performing organization leading to turn around and high-powered growth. Identified business opportunities and leverage competencies to reduce costs, improve performance, and strengthen the bottom line. Achieved consistent success in identifying opportunities for product launches and accelerated growth. Devised planning strategies for large-scale programs as well as providing drug research and tactical marketing. Combined visionary leadership, mentoring, and communication skills with strong organizational achievements. Managed multi-million dollar research budget that includes globally distributed research laboratories and staff of 1200 medical professionals. Implement strategic and business plans to meet deadlines for medical and research goals. Served in the Navy for 16 years with the rank of Commander. Oversaw all endemic infectious disease and contributed to research in the Middle East, Indochina, South America, and Africa. Board Certified in Internal Medicine and Infectious Diseases.

- Excellent mediation, negotiation, and facilitation skills
- Designed and managed multi-tired research projects in the areas of epidemiology & biostatistics
- Headed quality and assurance and risk management committee
- Performed financial planning and analysis
- Oversaw administrative and business infrastructure
- In charge of team building and performance management
- Performed complex financial analysis and modeling
- Staff internist at 65-bed community hospital practicing internal medicine.

PROFESSIONAL EXPERIENCE

2003-2005

DIRECTOR, MEDICAL RESEARCH AND DEVELOPMENT

National Naval Medical Center, Bethesda, Maryland

- Manage 10 globally distributed research laboratories with an annual budget of \$200-250 million dollars that employs 1200 people. Spear headed plan for research and development programs that resulted in implementation of a three-year strategic plan, one full year ahead of schedule. In charge of 74 research and development projects and the Malaria Genome Project. Areas of research target human performance, medical treatments, and medical countermeasures to increase combat readiness.
- Develop an Enterprise Business Architecture for managing value streams and internal business processes of R & D.
- Create and implement a Human Capital Strategy that reduces personnel costs by 20%. Downsizing and turn around decisions, resulted in dramatic improvements in operation, cost structures, and profitability achieved through reorganization.
- Manage infrastructure that reduced existing footprint by 50%; long-term facilities maintenance by 60%; and duplication of efforts in scientific programs by 40%.
- During tenure produced the following intellectual property; 38 patent application filings; Issued 10 patents, seven technology-licensing agreements, and 150 new cooperative research and development agreements.

Select Portfolio of Product Research & Development

- Phase 3 pivotal trial of Pneumococcal vaccine in 75,000 subjects
- Phase 3 clinical trial of N-acetylcysteine to treat acute acoustic barotraumas
- Phase 3 pivotal trial of a hemoglobin-based oxygen carrier (blood substitute)
- Phase 3 clinical trial of adenovirus vaccine
- Phase 3 clinical trial of Tafenoquine to prevent malaria
- Phase 3 clinical trial of Malarone to prevent malaria
- Phase 3 clinical trial of a Yellow Fever vaccine

Malaria Genome Project

- | | | |
|--|--|--|
| · Nucleic acid vaccines for malaria | · Nucleic acid vaccines for dengue fever virus | · Vaccines to prevent Rickettsial infections |
| · Vaccines to Prevent Traveller's Diarrhea | · Whole Blood substitutes | · Ex-vivo culture system for stem cell expansion |
| · Cellular therapies for radiation injury | · Therapies for laser-induced ocular injury | · Non-compressive therapies for decompression sickness |
| · Monoclonal antibody for post-exposure prophylaxis of anthrax | · Magnetic Lateral Flow Assays for Biowarfare agents | · Magnetic Lateral Flow Assay for rapid Tuberculosis screening |
| · Emergency (self administered) dental amalgam | · Reduced Oxygen Breathing Device | · Radiofrequency ID system for patient tracking |
| · Shipboard Forward Resuscitative Surgical System | · Laser Event Recorder | · Electronic Stethoscope |

1997-2003

CHIEF OPERATIONS OFFICER, U.S. Naval Medical Research Unit

- As Chief Operating Officer at NMCR, the Navy's largest biomedical research laboratory, with an annual budget of 100 million dollars, over saw the operation of the lab as well as four subordinate research labs that employed 750 people.
- Designed and managed all strategic planning for the research laboratory as well as execution of goals and objectives in support of annual business plans. Recognized for outstanding research, product development, and project management.
- Managed resource management, intellectual property, technology transfer, public affairs and marketing, human resources, equal opportunity, laboratory safety, human animal use, IM/IT and facilities.

1998-2001

INFECTIOUS DISEASES PROGRAM MANAGER, U.S. Navy,

- Responsible for implementation of all infectious disease research in the U.S. Navy. Co-managed the entire DOD program with the Army and Air force.
- Supported the following areas of research in product development for \$150-200 million dollars of research assets: Malaria vaccine and drug development, HIV vaccine and therapeutic development, rapid diagnostic development, and biologic and chemical defense.
- Explored concept development and basic scientific and proof-of-concept research, clinical trials, and licensure. One of the by products of the program was patented intellectual property. The program worked with many commercial partners involved in the execution of research that included laboratories based in the U.S., Indochina, the Middle East, Africa and South America.

1997-2001

PROGRAM MANAGER FOR THE DoD GLOBAL EMERGING INFECTIOUS SYSTEM, U.S. Navy,

- Managed six million dollar budget for five DOD overseas laboratories. In charge of prioritization of surveillance activities, review of proposals for scientific and epidemiological merit, determination of funding levels, review of program progress, data compilation and analysis, and data presentation.
- Engaged in extensive interaction with command and scientific staff at five laboratories. Integrated the DoD program with other Federal and International agencies, as well as foreign Ministries of Health and U.S. Diplomatic Missions.

1998-2001

- Acted as Navy Representative to the ASBREM's Joint Technological Coordinating Group Number Two (Infectious Disease Research) and Number Four (Biological Defense Research).

1999-2001

- During medical training was representative to the Navy's ASBREM's Joint technology coordinating group to (Infectious Disease Research).

Board Member

- Member of the Navy Epidemiology Board that is composed of ten members from four DoD services. Served in an advisory capacity to the Bureau of Medicine and Surgery. Represented the Infectious diseases research and development community and DoD.

Professional Societies

- American College of Physicians
- Infectious Disease Society of America

Education

Canisius College, Buffalo, New York, *Bachelor of Arts, 1979*

Georgetown University, Washington, D.C., *Master of Science in Physiology, 1981*
Georgetown University School of Medicine, Washington, D.C., *Doctor of Medicine, May, 1986*

Uniformed Services of University of Health Sciences, Department of Preventive Medicine and Biometrics, Bethesda, MD, *Masters Degree in Public Health, 1997;*
Track: Quantitative Data Analysis and Study Design

University of Maryland University College, College Park, MD. *Masters Degree in Management Technology and Innovation, 2000*